New York, USA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Chronic Obstructive Pulmonary Disease Market to Witness Upsurge in Growth During the Forecast Period (2023–2032), Assesses DelveInsight | Key Companies - Genentech, GlaxoSmithKline, Regeneron, Sanofi, AstraZeneca, Mereo, Inmunotek
The dynamics of the chronic obstructive pulmonary disease market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies.
DelveInsight’s Chronic Obstructive Pulmonary Disease Market Insights report includes a comprehensive understanding of current treatment practices, COPD emerging drugs, market share of individual therapies, and current and forecasted COPD market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Chronic Obstructive Pulmonary Disease Market Report
- As per DelveInsight’s analysis, the COPD market size was found to be USD 12.3 billion in 2022 in the 7MM and it is anticipated to grow at a significant CAGR by 2032.
- As per DelveInsight estimates, the diagnosed prevalent population of COPD in the 7MM was ~33 million in 2022. These cases of COPD in the 7MM is expected to increase throughout the study period (2019–2032).
- Leading COPD companies such as Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tetherex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, and others are developing novel COPD drugs that can be available in the COPD market in the coming years.
- Some of the key therapies for COPD treatment include Astegolimab (MSTT1041A, AMG 282, RG6149), SB240563 (Mepolizumab)/NUCALA, Ensifentrine (RPL554), Itepekimab/SAR440340/REGN3500, Dupilumab/SAR231893 (Dupixent), Tozorakimab (MEDI3506), FASENRA (Benralizumab), Tezspire (Tezepelumab), EP395, SelK2, Mitiperstat (AZD4831), CHF6001/Tanimilast, SNG001 (IFN-β), Acumapimod (BCT-197), Zofin, PUL-042, MV130, GSK3923868, PUR1800, GRC 39815, DMX-700, and others.
Discover which therapies are expected to grab the major COPD market share @ Chronic Obstructive Pulmonary Disease Market Report
Chronic Obstructive Pulmonary Disease Overview
Chronic obstructive pulmonary disease (COPD) is a frequently encountered and controllable ailment characterized by persistent respiratory symptoms and restricted airflow. These symptoms typically arise from extended exposure to harmful particles or gases, with tobacco smoking being the leading risk factor. However, other environmental factors such as biomass fuel exposure and air pollution may also contribute to its development. In addition to environmental influences, host factors can predispose individuals to COPD.
Chronic and progressive shortness of breath stands out as the most prominent symptom in COPD. Roughly 30% of patients also experience a persistent cough accompanied by sputum production. These symptoms can fluctuate from day to day and may manifest years before the emergence of airflow restriction. If a patient presents with dyspnea, a chronic cough, sputum production, or a history of exposure to risk factors associated with COPD, it's essential to consider the possibility of this condition. A definitive diagnosis in such cases necessitates spirometry testing; the presence of a post-bronchodilator FEV1/FVC ratio below 0.70 serves as confirmation of persistent airflow limitation.
Chronic Obstructive Pulmonary Disease Epidemiology Segmentation
The COPD epidemiology section provides insights into the historical and current COPD patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The COPD market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total COPD Diagnosed Prevalent Cases
- COPD Gender-specific Diagnosed Prevalent Cases
- COPD Age-specific Diagnosed Prevalent Cases
- Diagnosed Prevalent Cases of COPD Based on Severity of Airflow
- Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History COPD
Download the report to understand which factors are driving COPD epidemiology trends @ COPD Epidemiological Insights
Chronic Obstructive Pulmonary Disease Treatment Market
Many individuals with COPD experience mild forms of the condition that may require minimal intervention, primarily centered around smoking cessation. For those in more advanced stages of the disease, effective treatments are available to manage symptoms, slow disease progression, lower the risk of complications and exacerbations, and enhance their capacity to lead an active life. The overarching objective of COPD treatment is to facilitate easier breathing and a return to regular activities. Numerous medical interventions and lifestyle adjustments can contribute to achieving this goal.
Patients may also explore natural and alternative treatment options. COPD management primarily centers on alleviating symptoms like coughing and breathing difficulties while avoiding respiratory infections. Treatment strategies are often tailored to the specific stage of COPD. Furthermore, adopting certain lifestyle modifications is essential in preventing the onset of COPD. Foremost among these is smoking cessation, which plays a pivotal role in any COPD treatment plan. By quitting smoking, individuals can not only prevent further deterioration of their condition but also improve their respiratory function.
Moreover, individuals with COPD should be aware of the importance of getting vaccinated against influenza and pneumococcal pneumonia. This is crucial because those with COPD are more susceptible to serious complications from these diseases. As for medication, roflumilast (Daliresp), a phosphodiesterase-4 inhibitor, is approved for severe COPD and chronic bronchitis symptoms.
Learn more about the FDA-approved drugs for COPD @ Drugs for COPD Treatment
Key Chronic Obstructive Pulmonary Disease Therapies and Companies
- Astegolimab (MSTT1041A, AMG 282, RG6149): Genentech, Inc.
- SB240563 (Mepolizumab)/NUCALA: GlaxoSmithKline
- Ensifentrine (RPL554): Verona Pharma plc
- Itepekimab/SAR440340/REGN3500: Regeneron Pharmaceuticals/Sanofi
- Dupilumab/SAR231893 (Dupixent): Regeneron Pharmaceuticals/Sanofi
- Tozorakimab (MEDI3506): AstraZeneca/MedImmune LLC
- FASENRA (Benralizumab): AstraZeneca
- Tezspire (Tezepelumab): AstraZeneca
- EP395: EpiEndo Pharmaceuticals
- SelK2: Tetherex Pharmaceuticals
- Mitiperstat (AZD4831): AstraZeneca
- CHF6001/Tanimilast: Chiesi Farmaceutici S.p.A.
- SNG001 (IFN-β): Synairgen Research Ltd.
- Acumapimod (BCT-197): Mereo Biopharma
- Zofin: Organicell Regenerative Medicine
- PUL-042: Pulmotect, Inc.
- MV130: Inmunotek S.L.
- GSK3923868: GlaxoSmithKline
- PUR1800: PULMATRiX
- GRC 39815: GLENMARK PHARMACEUTICALS LTD
- DMX-700: Dimerix Limited
To know more about COPD clinical trials, visit @ COPD Treatment Drugs
The dynamics of COPD are anticipated to change in the coming years. In recent years, the incidence of COPD has surged significantly, primarily attributed to the rising rates of smoking and aging populations in numerous nations. As a result, there is an escalating need for fixed-dose combinations, as they have been shown to augment and extend the therapeutic benefits of individual components.
Furthermore, the COPD pipeline is very robust; many potential therapies are being investigated for the treatment of COPD, and it is safe to predict that the treatment space will significantly impact the COPD market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the COPD market in the 7MM.
However, several factors are impeding the growth of the COPD market. Inadequate comprehension of the clinical progression and its significance might result in a failure to arrive at the correct diagnosis. Additionally, the influx of generic alternatives can pose challenges for both established and emerging therapies, hindering potential profitability and impeding the growth of future COPD drug markets.
Moreover, COPD treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the COPD market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the COPD market growth.
|Chronic Obstructive Pulmonary Disease Report Metrics||Details|
|Chronic Obstructive Pulmonary Disease Report Coverage||7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]|
|Chronic Obstructive Pulmonary Disease Market Size in 2022||USD 12.3 Billion|
|Key Chronic Obstructive Pulmonary Disease Companies||Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tetherex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, and others|
|Key Chronic Obstructive Pulmonary Disease Therapies||Astegolimab (MSTT1041A, AMG 282, RG6149), SB240563 (Mepolizumab)/NUCALA, Ensifentrine (RPL554), Itepekimab/SAR440340/REGN3500, Dupilumab/SAR231893 (Dupixent), Tozorakimab (MEDI3506), FASENRA (Benralizumab), Tezspire (Tezepelumab), EP395, SelK2, Mitiperstat (AZD4831), CHF6001/Tanimilast, SNG001 (IFN-β), Acumapimod (BCT-197), Zofin, PUL-042, MV130, GSK3923868, PUR1800, GRC 39815, DMX-700, and others|
Scope of the Chronic Obstructive Pulmonary Disease Market Report
- Therapeutic Assessment: Chronic Obstructive Pulmonary Disease current marketed and emerging therapies
- Chronic Obstructive Pulmonary Disease Market Dynamics: Attribute Analysis of Emerging Chronic Obstructive Pulmonary Disease Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Chronic Obstructive Pulmonary Disease Market Access and Reimbursement
Discover more about COPD drugs in development @ COPD Clinical Trials
Table of Contents
|1.||Chronic Obstructive Pulmonary Disease Market Key Insights|
|2.||Chronic Obstructive Pulmonary Disease Market Report Introduction|
|3.||Chronic Obstructive Pulmonary Disease Market Overview at a Glance|
|4.||Chronic Obstructive Pulmonary Disease Market Executive Summary|
|5.||Disease Background and Overview|
|6.||Chronic Obstructive Pulmonary Disease Treatment and Management|
|7.||Chronic Obstructive Pulmonary Disease Epidemiology and Patient Population|
|9.||Chronic Obstructive Pulmonary Disease Marketed Drugs|
|10.||Chronic Obstructive Pulmonary Disease Emerging Drugs|
|11.||Seven Major Chronic Obstructive Pulmonary Disease Market Analysis|
|12.||Chronic Obstructive Pulmonary Disease Market Outlook|
|13.||Potential of Current and Emerging Therapies|
Chronic Obstructive Pulmonary Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted COPD epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Chronic Obstructive Pulmonary Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key COPD companies, including Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, Immunotek, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., Tetherex Pharmaceutical, CSL Behring, AstraZeneca, Novartis, Genentech, Vertex Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Foresee Pharmaceuticals, Amgen, Organicell Regenerative Medicine, Arrowhead Pharmaceuticals, ProterixBio, RS BioTherapeutics, MitoRx, C4X Discovery, Respiratorius, ARK biosciences, Incannex, GNI Pharma, Celon pharma, Alveolus Bio, Kinaset therapeutics, Landos Biopharma, Parion Sciences, KeyMed Biosciences, Bioneer corporation, AlgiPharma, Palobiofarma, Dimerix Bioscience, Glenmark Pharmaceuticals, among others.
Asthma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key asthma companies including GlaxoSmithKline, 4D Pharma plc, AstraZeneca, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Sinomab, Avalo Therapeutics, Kymab, Sanofi, Cumberland Pharmaceuticals, Genentech, Inc., among others.
Asthma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key asthma companies, including Jiangsu Hengrui Medicine, GlaxoSmithKline, Immunotek SL, AB Science, EMS, Avalo Therapeutics, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., ARS Pharmaceuticals, Sanofi, Zura Bio Ltd., AstraZeneca, EURRUS Biotech GmbH, T-Balance Therapeutics GmbH, Gossamer Bio, Aldeyra Therapeutics, Inc., Trio Medicines, Janssen Research & Development, Arrowhead Pharmaceuticals, Hoffman-La-Roche, GlaxoSmithKline, Biohaven Pharmaceutical, TAK-Circulator Co., Shanghai Hengrui Pharmaceutical, among others.
Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ARDS companies, including MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma, among others.
Acute Respiratory Distress Syndrome Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key acute respiratory distress syndrome companies, including Faron Pharmaceuticals, BioMarck Pharmaceuticals, Athersys, Apeiron Biologics, Cynata Therapeutics, Orbsen Therapeutics, GEn1E Lifesciences, Exvastat, Longeveron, CohBar, ZyVersa Therapeutics, Abbreos, Aviceda Therapeutics, ImStem Biotechnology, Bayer, AVM Biotechnology, Cartesian Therapeutics, Sage Therapeutics, Roivant Sciences, ZyVersa Therapeutics, Aerpio Pharmaceuticals, Apeiron Biologics, among others.
Other Trending Reports
Digestive System Fistula Market | Dementia With Diabetes Market | Leber's Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Frontotemporal Dementia Pipeline | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market
Related Healthcare Services
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.